Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
- 824 Downloads
Bortezomib and melphalan have synergistic effects against multiple myeloma (MM) cells. We conducted a pilot study on the combination of bortezomib and high-dose melphalan (Bor-HDM) as a conditioning regimen followed by autologous stem cell transplant (ASCT) in 17 Japanese patients with newly diagnosed MM, in comparison with a historical control of patients who received high-dose melphalan (HDM) only followed by ASCT. Nine patients received a single dose of bortezomib 1.3 mg/m2 on day −1 in combination with melphalan 100 mg/m2 on days −3 and −2 (Bor1-HDM), and eight received two doses of bortezomib 1.3 mg/m2 on days −4 and −1 (Bor2-HDM) in combination with HDM. Engraftment of autologous peripheral blood stem cells and regimen-related toxicities (RRT) were comparable among the HDM and Bor-HDM groups. Probability of upgrading from a less than very good partial response (VGPR) to VGPR after ASCT was approximately two times higher in the Bor-HDM group than in the HDM group. However, we observed no significant differences in engraftment, RRT, and response rates between the Bor1-HDM and Bor2-HDM groups. The present study showed that concurrent administration of at least two doses of bortezomib in combination with HDM can be safe in Japanese patients. Additional large prospective randomized trials are required to address the optimal dosages and schedules of bortezomib administration, as well as the efficacy of the Bor-HDM conditioning regimen for ASCT.
KeywordsBortezomib Melphalan Multiple myeloma Autologous Stem cell transplantation
We thank the nursing staff who cared for the patients at the Fukuoka BMT group. This work was supported, in part, by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology in Japan (23390254 & 24659462 to T.M.).
Conflict of interest
- 4.Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075–85.PubMedCrossRefGoogle Scholar
- 13.Palumbo A, Cavallo F, Hardan I, et al. Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 years: Results of a Randomized Phase III Study. Blood (ASH Annual Meeting Abstracts). 2011;118:3069.Google Scholar
- 18.Rowley S, Siegel D, Donato M, et al. Combination melphalan and bortezomib conditioning with autologous hematopoietic stem cell support in patients with advanced multiple myeloma. A phase I/II study. Blood (ASH Annual Meeting Abstracts). 2009;114:1214.Google Scholar
- 19.Wong Doo N, Thompson PA, Prince HM, et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma. 2012.Google Scholar
- 23.Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica. 2010;95:1913–20.PubMedCrossRefGoogle Scholar
- 24.Blanes M, Lahuerta JJ, Gonzalez JD, et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013;19:69–74.PubMedCrossRefGoogle Scholar
- 25.Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002;99:731–5.PubMedCrossRefGoogle Scholar
- 28.Takezako N, Sekiguchi N, Nagata A, Noto S, Miwa A. Conditioning for autlogous stem cell transplantation by combining bortezomib and dexamethasone with high-dose melphalan (BD-HDM) is feasible in young japanese multiple myeloma patients. Haematologica (13th IMW Abstracts). 2011;96:s93.Google Scholar
- 29.Huang W, Li J, Li H, et al. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leuk Lymphoma. 2012;53:2507–10.PubMedCrossRefGoogle Scholar